NASDAQ:NGNE Neurogene Q1 2025 Earnings Report $28.31 -2.94 (-9.41%) Closing price 09/25/2026 04:00 PM EasternExtended Trading$28.48 +0.17 (+0.60%) As of 09/25/2026 07:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Neurogene EPS ResultsActual EPS-$1.08Consensus EPS -$1.05Beat/MissMissed by -$0.03One Year Ago EPSN/ANeurogene Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/ANeurogene Announcement DetailsQuarterQ1 2025Date5/9/2025TimeBefore Market OpensConference Call DateFriday, May 9, 2025Conference Call Time7:30AM ETUpcoming EarningsNeurogene's Q3 2026 earnings is estimated for Thursday, November 12, 2026, based on past reporting schedules, with a conference call scheduled on Friday, November 13, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Neurogene Earnings HeadlinesNeurogene (NASDAQ:NGNE) Sees Unusually-High Trading Volume - Should You Buy?September 24 at 6:21 AM | americanbankingnews.comNeurogene to Participate in H.C. Wainwright 28th Annual Global Investment ConferenceSeptember 8, 2026 | businesswire.comMy top 3 AI picks for the next decadeAlexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up Amazon and Netflix under $3 per share in 2005. Now the chief investment strategist at The Oxford Club has identified three AI stocks he believes could be the most profitable investments of the next decade. | The Oxford Club (Ad)Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)September 4, 2026 | businesswire.comNeurogene Reports Second Quarter 2026 Financial Results and Highlights Recent UpdatesAugust 11, 2026 | businesswire.comNeurogene (NGNE) Receives a Buy from LifeSci CapitalJuly 12, 2026 | theglobeandmail.comSee More Neurogene Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Neurogene? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Neurogene and other key companies, straight to your email. Email Address About NeurogeneNeurogene (NASDAQ:NGNE) (NASDAQ: NGNE) is a clinical-stage biotechnology company focused on developing genetic medicines for patients with rare neurological diseases. The company’s research programs are designed to address disorders caused by genetic mutations for which existing treatment options are limited. Neurogene is developing an investigational gene therapy platform known as EXACT, which is intended to help regulate therapeutic gene expression and support the delivery of genetic medicines. Its pipeline includes NGN-401, an investigational therapy for Rett syndrome, and NGN-101, an investigational therapy being developed for CLN5 Batten disease, a rare neurodegenerative disorder. Founded in 2018 and based in New York, Neurogene conducts its development activities through clinical research and collaborations intended to advance treatments for patients with severe neurological conditions. The company’s programs remain investigational and have not been established as safe or effective by regulatory authorities.View Neurogene ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles MarketBeat Week in Review – 09/21 - 09/25Costco Ends Its Fiscal Year on a High Note, Eyes Big ExpansionCracker Barrel Stock Is Rallying Again, But the Turnaround Still Has a Traffic ProblemDarden Restaurants Serves Up Fresh Catalysts for a Stock Price RallySoFi Is Bypassing the Banking Bottleneck With Stablecoin SettlementSuper Micro’s Vera Rubin Shipments Put Its AI Infrastructure Advantage to the TestHims & Hers Slides Nearly 7% as Legal Pressure Adds to Its Growing List of Risks Upcoming Earnings Micron Technology (9/30/2026)NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)BlackRock (10/13/2026)Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
